Noxiousness of AB-CHMINACA
Introduction of AB-CHMINACA
AB-CHMINACA is a research chemical that is used as a potent agonist for the cannabinoid receptors, similar to that of cannabis the subjective effects are produced by AB-CHMINACA. In 2009, it was developed by Pfizer and introduced as a potential analgesic medication, however, it was never examined for human use.
AB-CHMINACA is just like other cannabinoids as it is insoluble in water but it dissolves in ethanol and lipids.
Chemistry of AB-CHMINACA
Because of the fact that it contains a substituted indazole core, AB-CHMINACA is regarded as a synthetic indazole cannabinoid chemical. At the R1 of the Indazole, a cyclohexylmethyl group is bound to the indazole core. With a carboxamide group, this indazole is substituted at R3. With an aminocarbonyl group at R1 and a methyl group at R2, the terminal anime of this carboxamide is bonded to a substituted propyl chain.
Pharmacology of AB-CHMINACA
AB-CHMINACA being a research chemical is a selective CB1 receptor agonist. At CB1 over CB2, it is approximately 30 times more active. At CB1 the reported EC50 values are 7.4 ± 1.5nM and at CB2 the reported values are 232.4 ± 231.2nM.
Toxicity and harm potential of AB-CHMINACA
The laboratory use of AB-CHMINACA has tested for various chemical effects and toxicity. But the effects of this research chemical have not been studied in any scientific context and the exact toxic dosage of AB-CHMINACA is still unknown. There are no such studies due to the fact that AB-CHMINACA has a very diminutive history of human dosage, therefore it should be uses for laboratory tests only.
A crystalline solid
210, 303 nm
Warning - this product is not for human or veterinary use.